NCT03745716: A trial that was reported late by Aprea Therapeutics
This trial has reported, although it was 186 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03745716 |
|---|---|
| Title | A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination With Azacitidine Versus Azacitidine Alone for the Treatment of (Tumor Protein) TP53 Mutant Myelodysplastic Syndromes |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 11, 2019 |
| Completion date | Nov. 27, 2020 |
| Required reporting date | Nov. 27, 2021, midnight |
| Actual reporting date | June 1, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 186 |